Anticipating sales declines, Allergan cuts 460

Reporting a decline in earnings, Allergan announced that it would lay off 5 percent of its staff, or about 460 workers, primarily in the U.S. and Europe. Hardest hit by the cuts will be sales and marketing staff, the company said, as it adjusts to the "reduced short-term sales outlook" for some of its businesses. Release

Suggested Articles

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.

Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.